97
Participants
Start Date
May 31, 2011
Primary Completion Date
April 30, 2013
Study Completion Date
April 30, 2013
GSK1120212
Starting dose based on GSK protocol MEK111054 and then dose escalation based on Dose Limiting Toxicities per protocol.
GSK1120212
Dose will be maximum tolerated dose based on Phase I results.
GSK Investigational Site, Leuven
GSK Investigational Site, Ghent
GSK Investigational Site, New York
GSK Investigational Site, Bornx
GSK Investigational Site, Lake Success
GSK Investigational Site, Marseille
GSK Investigational Site, Pittsburgh
GSK Investigational Site, Hershey
GSK Investigational Site, Toulouse
GSK Investigational Site, Birmingham
GSK Investigational Site, Duisburg
GSK Investigational Site, Münster
GSK Investigational Site, Mainz
GSK Investigational Site, Rochester
GSK Investigational Site, Lille
GSK Investigational Site, Frankfurt am Main
GSK Investigational Site, Chicago
GSK Investigational Site, Pierre-Bénite
GSK Investigational Site, Houston
GSK Investigational Site, Los Angeles
GSK Investigational Site, Duarte
GSK Investigational Site, Bobigny
GSK Investigational Site, San Francisco
GSK Investigational Site, Portland
GSK Investigational Site, Winston-Salem
GSK Investigational Site, Seattle
GSK Investigational Site, Dresden
GSK Investigational Site, Leipzig
Lead Sponsor
GlaxoSmithKline
INDUSTRY